Loading viewer...
investor_presentation
Format: PDF investor_presentation
Schrödinger presented its Q1 FY24 results focusing on accelerating drug development timelines and reducing R&D costs through science-based software and consulting solutions. The presentation discusses the company's competitive advantages, recent Immunetrics acquisition integration, and market position in the pharmaceutical software sector.
investor_presentation
TOCVAN
investor_presentation
Bidcorp